[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642170":3},{"organization":4,"outcomesModule":7,"designInfo":28,"detailedDescription":19,"studyPopulation":19,"armGroups":37,"interventions":58,"overallOfficials":70,"centralContacts":74,"locations":83,"responsibleParty":134,"collaborators":19,"id":136,"slug":137,"hasResults":138,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":19,"eligibilityCriteria":142,"healthyVolunteers":143,"sex":144,"minAge":145,"maxAge":146,"enrollmentInfo":147,"targetDuration":19,"studyType":150,"phases":151,"briefSummary":153,"conditions":154,"keywords":19,"overallStatus":86,"whyStopped":19,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":166},{"fullName":5,"class":6},"Eli Lilly and Company","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":19},[9,13],{"measure":10,"description":11,"timeFrame":12},"Part A and C: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration","A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module.","Baseline through end of the Follow-up (Week 25)",{"measure":14,"description":11,"timeFrame":15},"Part B: Number of Participants with One or More TEAEs and SAEs Considered by the Investigator to be Related to Study Drug Administration","Baseline through end of the Follow-up (Week 33)",[17,21,23,26],{"measure":18,"description":19,"timeFrame":20},"Part A and C: Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY4174794",null,"Predose on day 1 through end of the Follow-up Period (Week 25)",{"measure":22,"description":19,"timeFrame":20},"Part A and C: PK: Area Under the Concentration Versus Time Curve (AUC) of LY4174794",{"measure":24,"description":19,"timeFrame":25},"Part B: PK: Maximum Observed Drug Concentration (Cmax) of LY4174794","Predose on day 1 through end of the Follow-up Period (Week 33)",{"measure":27,"description":19,"timeFrame":25},"Part B: PK: Area Under the Concentration Versus Time Curve (AUC) of LY4174794",{"allocation":29,"interventionModel":30,"interventionModelDescription":19,"primaryPurpose":31,"observationalModel":19,"timePerspective":19,"maskingInfo":32},"RANDOMIZED","SEQUENTIAL","BASIC_SCIENCE",{"masking":33,"maskingDescription":19,"whoMasked":34},"DOUBLE",[35,36],"PARTICIPANT","INVESTIGATOR",[38,45,49,54],{"label":39,"type":40,"description":41,"interventionNames":42},"Part A: LY4174794","EXPERIMENTAL","Participants will receive LY4174794 administered subcutaneously (SC).",[43,44],"Drug: LY4174794","Drug: Placebo",{"label":46,"type":40,"description":47,"interventionNames":48},"Part B: LY4174794","Participants will receive LY4174794 administered SC.",[43,44],{"label":50,"type":51,"description":52,"interventionNames":53},"Part A & B: Placebo","PLACEBO_COMPARATOR","Participants will receive placebo administered SC.",[44],{"label":55,"type":40,"description":56,"interventionNames":57},"Part C: LY4174794","Participants will receive LY4174794 administered intravenously (IV).",[43],[59,64,67],{"type":60,"name":61,"description":62,"armGroupLabels":63,"otherNames":19},"DRUG","LY4174794","Administered SC.",[39,46],{"type":60,"name":61,"description":65,"armGroupLabels":66,"otherNames":19},"Administered IV.",[55],{"type":60,"name":68,"description":62,"armGroupLabels":69,"otherNames":19},"Placebo",[50,39,46],[71],{"name":72,"affiliation":5,"role":73},"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC\u002FGMT - 5 hours, EST)","STUDY_DIRECTOR",[75,80],{"name":76,"role":77,"phone":78,"phoneExt":19,"email":79},"Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or","CONTACT","1-317-615-4559","LillyTrials@Lilly.com",{"name":81,"role":77,"phone":19,"phoneExt":19,"email":82},"Physicians interested in becoming principal investigators please contact","clinical_inquiry_hub@lilly.com",[84,104,119],{"facility":85,"status":86,"city":87,"state":88,"zip":89,"country":90,"countryCode":91,"cosmosGeoPoint":92,"geoPoint":97,"contacts":98},"ICON Early Phase Services, LLC","RECRUITING","San Antonio","Texas","78232","United States","US",{"type":93,"coordinates":94},"Point",[95,96],-98.49363,29.42412,{"lat":96,"lon":95},[99,101],{"name":19,"role":77,"phone":100,"phoneExt":19,"email":19},"(210) 225-5437",{"name":102,"role":103,"phone":19,"phoneExt":19,"email":19},"Cassandra Key","PRINCIPAL_INVESTIGATOR",{"facility":85,"status":105,"city":106,"state":107,"zip":108,"country":90,"countryCode":91,"cosmosGeoPoint":109,"geoPoint":113,"contacts":114},"NOT_YET_RECRUITING","Salt Lake City","Utah","84124",{"type":93,"coordinates":110},[111,112],-111.89105,40.76078,{"lat":112,"lon":111},[115,117],{"name":19,"role":77,"phone":116,"phoneExt":19,"email":19},"801-261-3341",{"name":118,"role":103,"phone":19,"phoneExt":19,"email":19},"Ahad Sabet",{"facility":120,"status":105,"city":121,"state":19,"zip":122,"country":121,"countryCode":123,"cosmosGeoPoint":124,"geoPoint":128,"contacts":129},"Lilly Centre for Clinical Pharmacology","Singapore","138623","SG",{"type":93,"coordinates":125},[126,127],103.85007,1.28967,{"lat":127,"lon":126},[130,132],{"name":19,"role":77,"phone":131,"phoneExt":19,"email":19},"+65 6413 9811",{"name":133,"role":103,"phone":19,"phoneExt":19,"email":19},"Jennifer Boon Wee",{"type":135,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100642170","phase-1-a-study-of-ly4174794-in-participants-with-obesity-or-overweight-who-are-otherwise-healthy-100642170",false,"NCT07654972","A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy","A Phase 1, Randomized, Placebo-Controlled, Single- and Multiple-Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy","Inclusion Criteria:\n\n* Are overtly healthy with no comorbidities related to body mass index (BMI), such as type 2 diabetes mellitus or unstable cardiovascular disease\n* Are overweight with a BMI of ≥27 kilogram per meter square (kg\u002Fm²), or have obesity with a BMI of ≥30 kg\u002F m²\n* Have had a self-reported stable weight for 3 months prior to screening\n\nExclusion Criteria:\n\n* Have a history or presence of cardiovascular, respiratory, hepatic, renal, GI, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study intervention, or of interfering with the interpretation of data\n* Is an individual of childbearing potential (IOCBP)",true,"ALL","18 Years","65 Years",{"count":148,"type":149},108,"ESTIMATED","INTERVENTIONAL",[152],"PHASE1","The main purpose of this study is to understand how safe and well-tolerated LY4174794 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4174794 gets into the bloodstream and how long it takes the body to eliminate it.\n\nParticipation in this study will last about 30 to 39 weeks (7 to 10 months).",[155,156],"Obesity","Overweight","2026-08-28",{"date":159,"type":160},"2026-09-01","ACTUAL",{"date":162,"type":160},"2026-06-24",{"date":164,"type":149},"2029-04",{"name":5,"class":6},3]